HLB Science, which is developing a next-generation sepsis treatment, said on Friday that it signed a research agreement with NodCure, a company that has the technology to develop microbiome-based therapeutics for metabolic and immune diseases.Through this agreement, HLB Science will conduct joint re
Starting this month, Janssen's psoriasis treatment, Tremfya (ingredient: guselkumab), will be covered by the national health insurance for patients in Korea with palmoplantar pustulosis (PPP) treated with methotrexate or cyclosporine.Previously, Tremfya was only covered for patients with PPP treated
The Ministry of Food and Drug Safety (MFDS) said on Friday that it initiated administrative penalties and recall and destruction procedures against Huons BioPharma for the unauthorized sale of its botulinum toxin (BTX) Liztox Inj. 100 units without obtaining domestic export approval.The penalty incl
The nation’s health insurance review agency said Roche's Evrysdi (risdiplam), an oral treatment for spinal muscular atrophy (SMA), was deemed eligible for reimbursement. The decision came more than two years after Roche’s application.The Health Insurance Review and Assessment Service (HIRA) held the
Yuhan Corp. said on Tuesday it signed a licensing-in agreement with J INTS BIO for its HER2-targeting tyrosine kinase inhibitor (TKI), JIN-A04, to work on a treatment for non-small cell lung cancer (NSCLC).The total value of the agreement is 429.8 billion won (approximately $324.9 million), includin
NeoImmuneTech announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. National Institutes of Health (NIH), has commenced a nonclinical trial to evaluate the efficacy of NT-I7 in treating acute radiation syndrome (ARS).In December 2022, NeoimmuneT
CrystalGenomics said on Thursday that its partner Jiangsu Hengrui Pharmaceuticals submitted a biological license application (BLA) to the FDA on Wednesday for approval of camrelizumab in combination with apatinib as a first-line treatment for liver cancer.The BLA was submitted through Jiangsu Hengru
GC said it has received final approval from the Indonesian Ministry of Health and Welfare to build a blood products plant in the country and transfer technology. The company has yet to disclose the location of the plant.The Indonesian government had been selecting companies for the construction and
BMS Korea has announced that Inrebic (ingredient: fedratinib), its myelofibrosis drug, will now be covered by the national health insurance system in Korea starting from June 1.Inrebic is a second-line treatment for myelofibrosis that selectively inhibits the JAK2 gene mutation, and can help improve
HLB will be the newest member of the KRX300 Healthcare Index on the Korea Exchange (KRX) on June 9.The anticancer drug developer said Wednesday that it would be included in the KRX300 Healthcare Index next Friday when the KRX regularly changes its index.HLB was not included in the Healthcare Index b
SCM Lifescience, a company specializing in the research and development of cell therapies, said on Tuesday that its stem cell therapy for atopic dermatitis, SCM-AGH, demonstrated efficacy and safety in phase 2 clinical trials.The phase 2 study was conducted on 72 patients with moderate or severe ato
AbbVie Korea is strengthening its position in the local adolescent atopic dermatitis market with Rinvoq (ingredient: upadacitinib), a treatment for moderate to severe atopic dermatitis armed with new reimbursement benefits, the company said Tuesday.Rinvoq received expanded to include coverage for th
The Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) has welcomed the government’s additional designation of the industry to national high-technology strategic industries.“We sincerely welcome the government's designation of the biopharma industry as an additional national high-
SK Bioscience said on Tuesday that its homegrown Covid-19 vaccine, SKYCovione, obtained approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for the first and second primary series doses for adults aged 18 and over in England, Scotland, and Wales.Consequently, SKYCovione
CTC Bio said it has obtained marketing authorization for two oral dissolving film (ODF)-type erectile dysfunction treatments in three countries -- Thailand, Mexico, and Chile.The products approved for sale are reformulated versions of sildenafil (original: Viagra) and tadalafil (original: Cialis)."W
KoBioLabs said on Friday that it has been selected as a research institute of the Ministry of Trade Industry and Energy’s (MOTIE) Bio-Industry Technology Development Project to commercialize a microbiome therapeutic for treating severe autism spectrum disorders (ASD).The project aims to develop huma
A recently published study by the Karolinska Institute suggests that vaccines against smallpox given until the mid-1970s offer continuing cross-reactive immunity to mpox, previously known as monkeypox.Recently, the World Health Organization (WHO) lifted the Public Health Emergency of International C
DIGMBIO said on Friday that it signed a business agreement with Inno Pharma Screen (IPS) to develop KRAS anti-cancer drugs using molecular glue technology.DIGMBIO will apply the molecular glue technology from IPS in a joint development project to target intractable KRAS G12D-mutated pancreatic and c
Hanmi Pharm said it has made a poster presentation on the results of its study of efocipegtrutide, HM15211, at the ATS (American Thoracic Society) 2023 in Washington, D.C., on May 19 to 24 (local time).Efocipegtrutide is a LAPSTriple agonist applied by Hanmi's platform technology, “LAPScovery,” whic
Celltrion said on Friday it filed a marketing authorization application with the European Medicines Agency (EMA) for CT-P43, a biosimilar referencing Stelara (ingredient: ustekinumab) to treat autoimmune diseases.Stelara, the original drug, is an interleukin (IL)-12 and 23 inhibitor developed by Jan